Acacia names new board members
This article was originally published in Scrip
Executive Summary
Acacia Pharma, a company specializing in the development of drugs for supportive care, has named Scott Byrd and Christine Soden to its board of directors. Mr Byrd was most recently the chief commercial officer of Cadence Pharmaceuticals until the company's acquisition by Mallinckrodt Pharmaceuticals in March 2014. Previously, Mr Byed held a variety of US and global roles in sales, marketing, finance, manufacturing and strategic planning at Lilly.